AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01606436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00002923
Drug: KRN5500
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00459953
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.
Trial: NCT01911429
Drug: Placebo 40 or 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 40 or 80 mg once daily
Trial: NCT04488900
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04488900
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01790308
Drug: CSII
RxNorm normalized name: Continuous Subcutaneous Insulin Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous subcutaneous insulin infusion for 2\~4 weeks
Trial: NCT01035515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral capsule placebo comparator
Trial: NCT01035515
Drug: BIIB014 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral capsule 50mg BIIB014
Trial: NCT01035515
Drug: BIIB014 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral capsule 100mg BIIB014
Trial: NCT00793598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01853176
Drug: Standard bupivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00218322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
Trial: NCT03709160
Drug: Bumetanide 1 MG
RxNorm normalized name: bumetanide 1 MG
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all patients will be taking the treatment recommended by heart failure guidelines
Trial: NCT06083116
Drug: Hydrochlorothiazide、Henagliflozin Proline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide and Henagliflozin Proline
Trial: NCT00435292
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nonsteroidal anti-inflammatory drug
Trial: NCT02230930
Drug: Subcutaneous hydrocortisone 10mg
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
Trial: NCT04386122
Drug: JAPROLOX TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage: Single dose of one tablet of reference product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of reference product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
Trial: NCT00326326
Drug: CP-778,875
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03962920
Drug: Tigecycline 50 MG
RxNorm normalized name: tigecycline 50 MG
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local instillation of drug directly to the tumour tissue
Trial: NCT02179151
Drug: ZGN-440 Placebo for Injectable Suspension
RxNorm normalized name: placebo 440 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
Trial: NCT01751919
Drug: Glivec film-coated tablet 100 mg, 4 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00751829
Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
Trial: NCT00751829
Drug: nitrendipine + hydrochlorothiazide, if necessary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
Trial: NCT00381095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00720434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
Trial: NCT00275054
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cycles 1-6: 250 mg/m² i.v., d2-4, q28d
Trial: NCT00846430
Drug: Celecoxib (Celebrex)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: age and weight dependant
Trial: NCT00099853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin matching placebo
Trial: NCT00507962
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 20 mg/m\^2 IV On Day 1 Every 4 Weeks
Trial: NCT00317213
Drug: LIBERTAL- a phospholipid mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01014585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets administered orally twice daily
Trial: NCT02580331
Drug: SRP and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placement of placebo gel into classII furcation defects after scaling and root planing
Trial: NCT02808390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID for 8 Weeks
Trial: NCT04233060
Drug: CS3005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
Trial: NCT00905541
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/day
Trial: NCT00905541
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg simvastatin acute-on-chronic
Trial: NCT04174118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).
Trial: NCT02935309
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-surgery Capecitabine, 850 mg/m\^2, twice a day (BID) on days 1-5 for 5½ -6 weeks.
Trial: NCT03719157
Drug: intravenous patient controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.
Trial: NCT00456898
Drug: Codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03256149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (IV placebo)
Trial: NCT06000514
Drug: Sm29 Protein, Schistosoma Mansoni
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sm29 cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
Trial: NCT03824912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
Trial: NCT04055233
Drug: NaCl; saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm: irrigation of subcutaneous tissue after fascia closure with NaCl (one minute) A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.
Trial: NCT02199899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03174236
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
Trial: NCT00273013
Drug: GW274150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW274150 will be available as 30 mg white oval tablets.
Trial: NCT00273013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for Singulair and GW274150 will be available.
Trial: NCT00235963
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003063
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003063
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01407094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-4 pills per day
Trial: NCT02137967
Drug: 2.5% NaOCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01032148
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
Trial: NCT02901431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
Trial: NCT02901431
Drug: RO5285119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
Trial: NCT03132584
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~- Via IV Day 3
Trial: NCT00935389
Drug: tripterygium glycosides
RxNorm normalized name: anthraquinone glycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.
Trial: NCT01910675
Drug: FFP
RxNorm normalized name: ErgocaffPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 units Octaplas. Additional fibrinogen if needed.
Trial: NCT00488787
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01260103
Drug: ANP Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of ANP therapy are administered for 52 weeks. If the study subject has an OR or maintains SD, ANP therapy is continued.
Trial: NCT03849339
Drug: D635
RxNorm normalized name: FILTER,SUCTION DEVILBISS #7305D635
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug
Trial: NCT03682497
Drug: AZD9977
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9977 capsules taken orally for 28 days.
Trial: NCT03682497
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone tablets taken orally for 28 days.
Trial: NCT01021540
Drug: Repository corticotrophin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acthar 80 IU SQ once a week and titrated up to twice a week
Trial: NCT03515044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered twice daily (BID)
Trial: NCT00505843
Drug: MK0657
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7mg MK0657 capsules
Trial: NCT03553186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (200 cc sterile normal saline + placebo TXA ampule (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
Trial: NCT02847598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT00004059
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01352689
Drug: CKD-828(FDC)
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
Trial: NCT02309879
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
Trial: NCT01138956
Drug: Pentavalent antimonial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent antimonial, 20mg/kg/day, 28 days, IV
Trial: NCT00836355
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg orally once daily for 5 days
Trial: NCT03036293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use.
Trial: NCT03686397
Drug: SVT-15652
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vial twice daily
Trial: NCT03686397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vial twice daily
Trial: NCT01204138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID
Trial: NCT01469910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses: 150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
Trial: NCT00930059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets, every 12 hours for 12 wks
Trial: NCT04799041
Drug: GTX 2/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There were 15 patients in this group. Each one received only one treatment.
Trial: NCT04799041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There were 15 patients in this group. Each one received only one treatment.
Trial: NCT02399306
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the Trial Group received concurrent chemoradiotherapy and standardized, whole-course enteral nutrition management.
Trial: NCT03660787
Drug: Seroguard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seroguard 0.41 g/L solution
Trial: NCT03660787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT01542645
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl (12 mcg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
Trial: NCT01538420
Drug: GLPG0492
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT01538420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution
Trial: NCT00213005
Drug: Carraguard (PC-515)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00283842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00505843
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7mg MK0657 Pbo capsules
Trial: NCT00505843
Drug: Comparator: levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa \>/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period
Trial: NCT04013334
Drug: MTG201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50
Trial: NCT03797196
Drug: standard dose tacrolimus with mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A standard Tacrolimus once-daily (Envarsus) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
Trial: NCT03634735
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamine B1
Trial: NCT01238679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT02254486
Drug: NER1006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
Trial: NCT01176981
Drug: High Dose Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be given by IV at a dose of 12 gram/m2/dose.~The patient will receive 4-6 hours of hydration with alkalinization, and then HD MTX will be infused over 4 hours. Following this, the patient will be discharged home to receive continuous intravenous hydration through a portable pump. The patient will return to hospital daily for a comprehensive clinical assessment, IV hydration and antiemetics, MTX level and creatinine monitoring until MTX is cleared (3-4 days).
Trial: NCT01151696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00904280
Drug: Oxymorphone ER
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label
Trial: NCT01445860
Drug: Simvastatin/PF-03882845
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 20 mg simvastatin on Day 1, 30 mg PF-03882845 once daily from Days 2 to 13, the single dose 20 mg simvastatin on Day 12.
Trial: NCT02340962
Drug: TG-2349
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
Trial: NCT02115152
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02132104
Drug: Femoston
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormones treatment after surgery.
Trial: NCT02421341
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During study visits 2 and 3 you will receive an intrathecal (fluid filled space surrounding the spinal cord) injection of either fentanyl or placebo (saline). Fentanyl is an opiate (narcotic) drug and a common medication, however the way fentanyl is being used in this study is considered investigational.
Trial: NCT02421341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02115152
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02115152
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01320722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo soft gel once per week for 8 weeks
Trial: NCT01320722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)